Factors influencing the outcome of thyrostatic drug therapy in Graves' disease.
In patients with Graves' disease, thyrostatic drug treatment may induce definitive remission without the need of more aggressive measures such as surgery or radioiodine. Following drug therapy, however, relapses often occur. In the present study, a multivariate analysis of pretreatment variables was performed, in order to identify individuals running a high risk of an unfavourable outcome of thyrostatic drug therapy. We studied 109 consecutive patients with a mean age of 38 years, range 20-70, over a mean follow-up period of 5.3 years after cessation of therapy. The analysis showed that goitre size, age, thyroid hormone levels, HLA-DR 3 haplotype, and TSH receptor antibody levels were of prognostic significance, whereas HLA-B8 haplotype, a lymphocytic infiltrate at fine needle biopsy, thyroglobulin, and microsomal antibodies had no such value. In particular, patients characterized by young age, large goitre and high hormone values were found to be associated with an unfavourable course.
Winsa
B
B
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Dahlberg
A
A
Jansson
R
R
Agren
H
H
Karlsson
F A
FA
D000328:Adult; D000367:Age Factors; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006042:Goiter / Q000473:pathology; D006111:Graves Disease / Q000188:drug therapy*; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D015999:Multivariate Analysis; D011989:Receptors, Thyrotropin / Q000276:immunology; D013954:Thyroglobulin / Q000276:immunology; D013974:Thyroxine / Q000032:analysis / Q000627:therapeutic use*; D014284:Triiodothyronine / Q000032:analysis
D006680:HLA Antigens; D011989:Receptors, Thyrotropin; D014284:Triiodothyronine; D008713:Methimazole; D013954:Thyroglobulin; D013974:Thyroxine